Boehringer Ingelheim Reports 7.4% Sales Growth to €12.9 Billion in the First Half of 2024

Boehringer Ingelheim delivered a solid business performance in the first half of 2024, achieving a significant increase in net sales, up 7.4% year-on-year to €12.9 billion. This strong growth was mainly driven by the outstanding performance of its pharmaceutical business, in particular the market leadership of the Ou Tangjing ® and Vegat ® family products, which further consolidated the company's leading position in the global pharmaceutical industry.

In response to growing market demand, Boehringer Ingelheim has increased its investment in the production and supply network. Earlier this year, the company announced that it will invest €120 million to upgrade and expand its pharmaceutical facility in Koropi, Greece, to increase the capacity of new and existing products, including some innovative products in advanced development, to meet the high quality medicines that patients around the world have come to expect.

In key therapeutic areas, Boehringer Ingelheim has made significant progress. In the coming year, the company plans to release more positive results from clinical studies in areas such as oncology, mental health and pulmonary fibrosis. For example, Zongertinib in oncology, Iclepertin in mental health, and Nerandomilast in pulmonary fibrosis all show great potential to bring new treatment options to patients.

In the field of cardiorenal metabolic health, Boehringer Ingelheim's research has also achieved a milestone breakthrough. survodutide has shown encouraging results in a Phase II clinical trial for the treatment of steatohepatitis (MASH) associated with metabolic dysfunction, with 83% of patients achieving significant improvement after receiving the treatment. In addition, a subgroup analysis further confirmed that 64.5% of patients with moderate to advanced fibrosis improved their fibrosis degree and did not worsen their disease after treatment.

Boehringer Ingelheim has also initiated a number of Phase III clinical trials, including a novel selective aldosterone synthetase inhibitor (ASi) in combination with Englipzin for chronic heart failure, and a trial of ASi for chronic kidney disease in collaboration with Oxford Population Health to explore broader therapeutic possibilities.

In addition, Boehringer Ingelheim has a multi-year sponsorship agreement with the American Heart Association's Cardio-Renal Metabolic Health Initiative, which aims to gain a deeper understanding of the impact of cardio-renal metabolic related diseases on patients, leading to the development of more effective treatment strategies.

Boehringer Ingelheim's determination to return to the field of oncology therapy is also reflected in the fact that its HER2-specific tyrosine kinase inhibitor Zongertinib is currently in clinical study for HER2-variant cancers, promising to revolutionize treatment options in this field.

Boehringer Ingelheim's strong results and continued investment in innovation in the first half of 2024 demonstrate the company's solid development in the global pharmaceutical market and its strong commitment to the needs of patients.